|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/55 | |
| A61K 39/395 | |||
| A61P 35/02 | |||
| A61P 35/00 | |||
| A61K 45/06 | |||
| C07K 16/28 | |||
| C07K 16/32 |
| (11) | Number of the document | 2560658 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11772735.4 |
| Date of filing the European patent application | 2011-04-21 | |
| (97) | Date of publication of the European application | 2013-02-27 |
| (45) | Date of publication and mention of the grant of the patent | 2017-02-22 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2011/033500 |
| Date | 2011-04-21 |
| (87) | Number | WO 2011/133819 |
| Date | 2011-10-27 |
| (30) | Number | Date | Country code |
| 326406 P | 2010-04-21 | US |
| (72) |
HERSHBERG, Robert, US
|
| (73) |
VentiRx Pharmaceuticals, Inc.,
1191 Second Avenue, Suite 1105, Seattle, WA 98101,
US
|
| (54) | ENHANCING ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY |
| ENHANCING ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY |